Drug intelligence / Profile preview

aminorex

Development stage
Discontinued
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Oral
01

Overview

Aminorex is an amphetamine-like anorectic agent that was developed and marketed in the 1960s as an appetite suppressant for weight loss. It acts as a central nervous system stimulant and functions primarily as a serotonin–norepinephrine–dopamine releasing agent (SNDRA), increasing the release of these monoamines in the brain. Aminorex also acts as a weak agonist at serotonin 5-HT2 receptors, including subtypes 5-HT2A, 5-HT2B, and 5-HT2C. The drug was withdrawn from the market after being linked to outbreaks of severe pulmonary hypertension, particularly in Europe, where it caused significant morbidity and mortality among users. Aminorex is now classified as a Schedule I controlled substance in the United States due to its high potential for abuse and lack of accepted medical use[1][2][3][4][5][7].

Brand names
MenocilApiquel
Other names
aminorexum
02

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on aminorex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aminorex.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call